Heartflow CEO John Farquhar sells over $1.8m in company stock

Heartflow CEO John C.M. Farquhar made a significant move by selling over $1.8 million worth of the company's common stock. The transactions occurred over two days in mid-September 2026, with Mr. Farquhar trading 38,900 shares in total. On September 10, he sold 35,010 shares at an average price of $46.4183 per share, executing multiple trades between $45.43 and $47.78.

The following day, he sold an additional 3,890 shares at $50.00 per share. These sales were conducted under a Rule 10b5-1 trading plan, which Mr. Farquhar established on September 12, 2025. Following these transactions, Mr. Farquhar still holds 321,914 shares of Heartflow common stock. The company's stock has been trading near its 52-week high of $51.78, delivering a 142% return over the past six months.

Despite the stock appearing overvalued relative to its Fair Value, Heartflow reported a narrower-than-expected loss for the second quarter of 2026, with adjusted earnings at negative $0.07 per share and revenue increasing by 48% to $64.1 million. This growth was driven by increased demand for HeartFlow's coronary artery disease diagnostics.

Stifel raised its price target for HeartFlow shares to $45 from $40, while maintaining a Buy rating, citing strong performance of HeartFlow's plaque and FFRCT businesses.